White House proposes to 'march in' on patents for costly drugs
To lower drug prices, the Biden administration is looking to assert its authority to license drug patents that rely on government-funded research to drugmakers that would offer cheaper medicines.
The Biden administration is taking another crack at high prescription drug prices. This time its sights are set on drugs that rely on taxpayer-funded inventions.
The federal government spends billions of dollars a year on biomedical research that can – and often does – lead to prescription drugs.
For years, activists have pushed the government to use so-called march-in rights when a taxpayer-funded invention isn't publicly available on reasonable terms. They
